PatientsVille.com Logo

Schizophrenia, and Solian

PatientsVille

Schizophrenia, Symptoms and Causes

Schizophrenia is a serious brain illness. People who have it may hear voices that aren't there. They may think other people are trying to hurt them. Sometimes they don't make sense when they talk. The disorder makes it hard for them to keep a job or take care of themselves.

Symptoms of schizophrenia usually start between ages 16 and 30. Men often develop symptoms at a younger age than women. People usually do not get schizophrenia after age 45. There are three types of symptoms:

  • Psychotic symptoms distort a person's thinking. These include hallucinations (hearing or seeing things that are not there), delusions (beliefs that are not true), trouble organizing thoughts, and strange movements.
  • "Negative" symptoms make it difficult to show emotions and to function normally. A person may seem depressed and withdrawn.
  • Cognitive symptoms affect the thought process. These include trouble using information, making decisions, and paying attention.

No one is sure what causes schizophrenia. Your genes, environment, and brain chemistry may play a role.

There is no cure. Medicine can help control many of the symptoms. You may need to try different medicines to see which works best. You should stay on your medicine for as long as your doctor recommends. Additional treatments can help you deal with your illness from day to day. These include therapy, family education, rehabilitation, and skills training.

NIH: National Institute of Mental Health

Check out the latest treatments for schizophrenia,

schizophrenia, treatment research studies

Solian clinical trials, surveys and public health registries


Find Drug Side Effect reports



Solian Side Effects

Insomnia (14)
Extrapyramidal Disorder (6)
Tremor (6)
Muscle Rigidity (5)
Increased Appetite (5)
Aggression (5)
Confusional State (4)
Platelet Count Decreased (4)
Vomiting (4)
Long Qt Syndrome (3)
Malaise (3)
Agitation (3)
Tachycardia (2)
Psychotic Disorder (2)
Mania (2)
Off Label Use (2)
Angioedema (2)
Nausea (2)
Speech Disorder (1)
Somnolence (1)
Stress (1)
Treatment Noncompliance (1)
Ventricular Fibrillation (1)
Skin Discolouration (1)
Weight Increased (1)
Suspiciousness (1)
Overdose (1)
White Blood Cell Count Decreased (1)
Nocturnal Fear (1)
Psoriasis (1)
Psychiatric Decompensation (1)
Pyrexia (1)
Psychomotor Hyperactivity (1)
Rash (1)
Ileus (1)
Neoplasm Skin (1)
Immunodeficiency (1)
Myoclonus (1)
Liver Function Test Abnormal (1)
Incoherent (1)
Leukopenia (1)
Hyperthermia (1)
Hyperhidrosis (1)
Haemodialysis (1)
Nephritis Interstitial (1)
Haemodynamic Instability (1)
Hallucination, Auditory (1)
Hypercreatininaemia (1)
Hospitalisation (1)
Neuroleptic Malignant Syndrome (1)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Can it be a side effect of Solian if I had MASTYTIS (inflammation of breast) recently and rather much matter evacuated? I have been using Solian for about 8 - 9 months. My diagnosis is smth. schizotypical & depressive. Besides, I have been taking

Has Solian ever had a diagnosis of Violent Tendencies for a schitzaphrenic patient??

Hi! I've been taking 50-100mg of solian/ amisulpride and I have been in remission of schizophrenia for years on it. I don't get any bad side effects and i get the pleasant side effect of euphoria on it. It's taken me years to find solian, and the oth

I am taking Solian 200mg a night for the last 7 years. I feel really lazy and just can't wake up early in the morning. I feel really agitation, depressedand anxiety sometimes.Solian seems to be a lot

I have been taking Solian for about 5 years and I have gained 20kg during that time. I feel hot all the time and can't survive without a fan or a/c on. I am edgy and irritable and often snap over insignificant, trivial things. I'm scared of going of

I have been taking solian for at least five years on and off ive taking small dose but still have mood swings nervous tension i develop sweating of the hands my face goes red i feel like my body is overheating

I have been taking solian for over 8 years now, and I extremely overweight, before I was athletic now walking down or up the street is a hassle, I breath fast get heaps dizzy when I cough find it hard to catch my breath, I feel heavy all over my hand

I have been treated with Solian for 12 years Im female 37 I have not had my periods for 12 years I regularly suffer from hyper anxiety diahorrea muscle twitching muscle spasms and stiffness I am always exhausted my breasts leak a milky substance and

I have been treating with solian for 1 year.i have not have regular period.i put weight about 20 kilos.my breasts leak a milky substance.i am sometimes very nervous.i see a psychiatrist.i sometimes have flashbacks of when i had my trauma.

I used to weigh 145 pounds now i weigh 260 pounds. i get palpitations. i have a lot of mood swings. sometimes i get chestpain. my sex life is not enjoyable. my erections are not full 100 percent.&

<span style='color: #808080;'><b>Describe Your Schizophrenia from HPV (GARDASIL) 2007 Experience Here:My 15 year old sonjust received first vaccination for HPV, nine days later experienced a psychotic disorder for one week, now

Hi! I've been taking 50-100mg of solian/ amisulpride and I have been in remission of schizophrenia for years on it. I don't get any bad side effects and i get the pleasant side effect of euphoria on it. It's taken me years to find solian, and the oth

I have been on Clopixol since 5 years and it has solved my problem (a mild form of schizophrenia), I heard voices and was a little bit too aggressive. But now I've put on these 10 kgs...

I have been prescribed Haloperidol for my acne. I have come to know that this is a drug for Schizophrenia - Why is this drug prescribed to me by my dermatologist ? Should I stop or continue ?

I just begun to take zeldox and I like it because my other pills made me sick. I noticed that I feel relaxed, sleepy and less nervous. I have schizophrenia, which i think i read somewhere is related to Parkinsons (dangerous!), so i like the pills.

I was on resperidone 4mg as well as Seriquel 600mg and i gained about 60 pounds on them so i stopped them as well and ended up in the hospital and they started me on the zeldox. Its helping my schizophrenia but its making me exhausted and not sleep a

My Mom was given Nuvigil for approximately six months. After stopping the drug, she has developed psychotic symptoms. She has recently been hospitalized and diagnosed with paranoid schizophrenia. She is 59 years old and never had any psychosis bef

My mother is suffering from schizophrenia, i found her not mentally satisfied not everything looking good to her still she holds the whole house but sometimes she feels like restless....

Safest antidepressant in conjuction with Amisulpride for treatment of depression associated with Schizophrenia. Thanks

Schizophrenia, Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients
Conditions: Schizophrenia;   Treatment Resistant Disorders
Interventions: Drug: Clozapine;   Drug: Amisulpride;   Drug: Clozapine+Amisulpride
Outcome Measures: Change from baseline in Positive and Negative Syndrome Scale (PANSS);   Change from baseline in Clinical Global Impression - Severity (CGI-S);   Change from baseline in Beck Depression Inventory (BDI);   Change from baseline in Beck Anxiety Inventory (BAI);   Change from baseline in Schizophrenia Quality of Life Scale (SQLS);   Change from baseline in Simpson-Angus Scale (SAS);   Change from baseline in Clozapine Adverse Effects Inventory (CAEI)
2 Recruiting Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy
Conditions: Schizophrenia;   Schizoaffective Disorder
Interventions: Drug: Olanzapine;   Drug: Amisulpride;   Drug: Olanzapine and Amisulpride
Outcome Measures: Symptomatic improvement of schizophrenia after 8 weeks of treatment in comparison to time of inclusion of patient measured py Positive and Negative Symptom Scale (PANSS);   Symptomatic improvement of schizophrenia after 16 weeks of treatment in comparison to time of inclusion of patient measured py PANSS total score reduction;   Symptomatic improvement of schizophrenia from baseline to week 2 up to week 16 measured by PANSS total score reduction.;   PANSS total score reduction from baseline to week 2 as a predictor of the change after 8 weeks;   Serious adverse drug reactions;   Change of clinical condition measured by Clinical Global Impression Scale (CGI scale);   Change of the subjective well-being measured by Subjective Wellbeing under Neuroleptics Scale (SWN-K)
3 Recruiting Optimisation of Antipsychotic Drug Use in Older People
Conditions: Alzheimer's Disease;   Schizophrenia
Intervention: Drug: amisulpride
Outcome Measures: Dopamine D2/3 receptor occupancy at steady state (4 days) treatment with 50mg amisulpride;   Dopamine D2/3 receptor occupancy during 4-10 weeks treatment with 50-200mg amisulpride;   neuropsychological test performance
4 Unknown  Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Amisulpride;   Drug: placebo
Outcome Measures: Total score on the Positive and Negative Syndrome Scale;   Social and Occupational Functioning Assessment Scale;   Calgary Depression Rating Scale for Schizophrenia;   Schedule for the Assessment of Insight;   Service Engagement Scale;   Antipsychotic Non-Neurological Side Effects Scale
5 Recruiting The Effects of Dopamine on Reward Processing
Condition: Major Depressive Disorder (MDD)
Interventions: Drug: Amisulpride;   Drug: Placebo
Outcome Measures: Performance on a behavioral task assessing learning from positive and negative feedback.;   Brain activation during a task involving monetary rewards.;   Brain activation to social positive and negative feedback;   Ratings of mood and affect.
6 Recruiting An Investigation of Early Life Stress and Depression
Conditions: Major Depressive Disorder (MDD);   History of Childhood Sexual Abuse (CSA)
Interventions: Drug: Amisulpride;   Drug: Placebo
Outcome Measures: Event-related potentials (ERPs);   Behavioral Performance in Probabilistic Reward Task (PRT);   Cortisol levels;   Brain activity and structure (MRI Data);   Behavioral Performance in Monetary Incentive Delay (MID) task;   Behavioral performance in the Probabilistic Stimulus Selection Task (PSST);   Dopamine Transporter Levels;   Ratings of Mood and Affect
7 Recruiting Optimization of Treatment and Management of Schizophrenia in Europe
Conditions: Schizophrenia;   Schizophreniform Disorder;   Schizoaffective Disorder
Interventions: Drug: Amisulpride open label;   Drug: 6-week amisulpride double blind treatment;   Drug: 6-week olanzapine double blind treatment;   Drug: 12-week clozapine open-label treatment;   Behavioral: Psychosocial intervention
Outcome Measures: PANSS;   Sellwood rating scale;   Biological profile;   MRS measures;   SOFAS global functioning;   MRI assessments;   All cause treatment discontinuation;   All cause discontinuation;   Biological markers
8 Recruiting Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen
Conditions: Schizophrenia;   Schizophreniform Disorder;   Schizoaffective Disorder
Intervention: Drug: Amisulpride
Outcome Measures: Relationship between specific neuropsychiatric measures and global improvement on PANSS scores;   Effect of antipsychotic medication on the D2 binding potential (SPECT) in antipsychotic naive patients with schizophrenia.;   Effect of antipsychotic medication on P50-suppression;   Effect of antipsychotic medication on the human reward system;   Change in hippocampal and basal ganglia volume from baseline to follow-up.;   Change in processing speed over time after antipsychotic treatment.;   Change in levels of brain perfusion from baseline to follow-up.
9 Recruiting Bergen Psychosis Project 2 - The Best Intro Study
Conditions: Schizophrenia;   Psychotic Disorders
Interventions: Drug: Amisulpride;   Drug: Aripiprazole;   Drug: Olanzapine
Outcome Measure: Change of the Positive and Negative Syndrome Scale total score
10 Recruiting Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics
Condition: Schizophrenia
Interventions: Drug: SEP-363856;   Drug: Amisulpride;   Drug: Placebo
Outcome Measures: BOLD fMRI activity in key regions of interest (ROIs) while performing the Monetary Incentive Delay (MID), N-back, and Signal detection (SD) tasks after a single-dose of study medication;   Behavioural performance in the MID task, includes measurements of trial accuracy, trial duration, trial reaction time and amount of money won.;   Behavioural performance in the N-back task, includes measurements of accuracy (% correct for each trial type), reaction time and target sensitivity (d').;   Behavioural performance in the SD task, includes measurements of correct and incorrect responses.
11 Recruiting Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)
Condition: Schizophrenia
Interventions: Drug: amisulpride;   Drug: aripiprazole
Outcome Measures: Relationship between specific neuropsychiatric measures and global improvement on PANSS scores;   The relation between D2 binding potential (SPECT) and reward related brain activity (fMRI BOLD response) before and after D2 antagonism;   Time/dose improvement on P50 suppression after antipsychotic treatment;   Disturbances in reward related fMRI BOLD response in antipsychotic naive schizophrenic patients;   Hippocampal loss and basal ganglia increase after antipsychotic treatment;   Processing speed improvement over time after antipsychotic treatment;   The effect of D2 blockade on reward related fMRI BOLD response
12 Recruiting Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study
Condition: Schizophrenia
Interventions: Drug: Cannabidiol CR;   Drug: Cannabidiol;   Drug: Amisulpride;   Drug: Olanzapine;   Drug: Quetiapine;   Drug: Risperidone;   Drug: Placebo
Outcome Measures: Plasma levels of cannabidiol;   Area Under Curve (AUC);   serum antipsychotic concentration
13 Recruiting The Switch Study - Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Schizophreniform Disorder
Intervention: Drug: Olanzapine or amisulpride
Outcome Measures: Number of patients in remission at week 8 comparing the "switched" with the "non switched" early non-responders);   PANSS total score change;   Cost of care;   Safety: Simpson-Angus Scale, Barnes Akathisia Scale, open interviews
14 Recruiting Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis
Condition: Psychosis Nos/Other
Interventions: Drug: Discontinuation antipsychotic treatment;   Drug: Antipsychotic treatment
Outcome Measure: Risk of relapse
15 Recruiting European Phase III Study of APD421 in PONV
Condition: PONV
Interventions: Drug: APD421;   Drug: Placebo
Outcome Measure: Complete Response (protection from PONV)
16 Recruiting US Phase III Study of APD421 in PONV
Condition: PONV
Interventions: Drug: APD421;   Drug: Placebo
Outcome Measure: Complete Response (protection from PONV)
17 Not yet recruiting A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients
Condition: Schizophrenia
Interventions: Drug: Cannabidiol;   Drug: Olanzapine;   Drug: Placebo Cannabidiol;   Drug: Placebo Olanzapine
Outcome Measures: Change in the Positive and Negative Syndrome Scale (PANSS) total score;   Changes in the PANSS subscores and clusters;   Changes in the Clinical Global Impression score;   Changes in the Global Assessment of Functioning Scale;   Changes in the Personal and Social Performance Scale;   Changes in the Calgary Depression Scale for Schizophrenia;   Changes in the Hamilton Anxiety Scale;   Changes in cognitive skills;   Response to antipsychotic medication;   Plasma levels of endogenous cannabinoids;   Changes in physiological parameter;   Changes in the UKU Side Effect Rating Scale;   Columbia Suicidality Severity Rating Scale
18 Unknown  Metabolic Side-effects for Second-generation Antipsychotics
Condition: Mental Disorders
Intervention:
Outcome Measure: